Author | Year | Type of study | Region | Breast cancer subtype | Number of patients ( high / low TMB) | Type of therapy | Outcome | Sample source | TMB detection method | TMB cutoff value | Median / average* TMB (Range) |
---|---|---|---|---|---|---|---|---|---|---|---|
Wen [31] | 2022 | Article | Multiple areas | HER2 +  | 216 ( 43 / 173) | Chemotherapy, Chemotherapy plus HER2 + targeted therapy | OS | tissue | NA | 3.05 Mut/Mb | 3.05 Mut/Mb* |
Liao(a) [29] | 2022 | Article | China | breast cancer | OS:139 ( 36 / 103) PFS:128 ( 29 / 99) | Chemotherapy, Endocrine therapy, Radiotherapy | OS, PFS | blood | NGS (PredicineCARE) | 4.3 Mut/Mb | 24.8 Mut/Mb ( 0–324) |
Liao(b) [29] | 2022 | Article | China | HER2 +  | 39 ( 13 / 26) | Chemotherapy, Endocrine therapy, Radiotherapy | OS | blood | NGS (PredicineCARE) | 4.3 Mut/Mb | NA |
Liao(c) [29] | 2022 | Article | China | TNBC | 34 ( 8 / 26) | Chemotherapy, Endocrine therapy, Radiotherapy | OS | blood | NGS (PredicineCARE) | 4.3 Mut/Mb | NA |
Makhlin [32] | 2021 | Conference abstratct | Multiple areas | breast cancer | 188 ( 13 / 175) | NA | OS | tissue | NA | 3 mutations | 2.2mutations* ( NA) |
Gao [33] | 2021 | Article | Multiple areas | TNBC | 101 ( 49 / 52) | NA | OS | tissue | NA | 1.26 Mut/Mb | 1.26 Mut/Mb ( 0.05–28.03) |
Anwar(a) [30] | 2021 | Article | China | HER2 +  | 28 ( 8 / 20) | HER2 + targeted therapy | OS, PFS | blood | NGS(OncoMD/OncoMD-Plus) | 5.0 Mut/Mb | 3.0 Mut/Mb (0–22) |
Anwar(b) [30] | 2021 | Article | China | HER2 +  with brain metastasis | 8 ( 6 / 2) | HER2 + targeted therapy | OS, PFS | blood | NGS(OncoMD/OncoMD-Plus) | 5.0 Mut/Mb | NA |
Chen [21] | 2020 | Article | China | HER2 +  | 28 ( 8 / 20) | HER2 + targeted therapy | PFS | blood | NGS(OncoMD/OncoMD-Plus) | 5.0 Mut/Mb | 3.0 Mut/Mb (0–22) |
Emens(a) [12] | 2020 | Conference abstratct | Multiple areas | TNBC | 579 ( 144 / 435) | ICIs | OS, PFS | tissue | NGS (FoundationOne) | 7.02 Mut/Mb | 4.39 Mut/Mb(0–46.51) |
Emens(b) [12] | 2020 | Conference abstratct | Multiple areas | TNBC (PD-L1-) | NA | ICIs | PFS | tissue | NGS (FoundationOne) | 7.02 Mut/Mb | NA |
Emens(c) [12] | 2020 | Conference abstratct | Multiple areas | TNBC (PD-L1 +) | NA | ICIs | PFS | tissue | NGS (FoundationOne) | 7.02 Mut/Mb | NA |
Barroso-Sousa [17] | 2020 | Article | Multiple areas | TNBC | 62 ( 12 / 50) | ICIs, ICIs plus Chemotherapy/ Targeted therapy | OS, PFS | tissue | NGS (OncoPanel) | 10 Mut/Mb | 6 Mut/Mb ( NA) |
Li [34] | 2020 | Article | Multiple areas | breast cancer | 44 (10% / 90%) | ICIs | OS | tissue /blood | NGS (MSK-IMPACT) | 6.8 Muts/MB | NA |
Samstein [22] | 2020 | Article | Multiple areas | breast cancer | 45 ( 12 / 33) | ICIs | OS | blood | NGS (MSK-IMPACT) | 5.9 Muts/MB | 3.94 Mut/Mb (0–46.52) |
Park [13] | 2018 | Article | Korea | HER2 +  | OS: 46 ( 16 / 30) PFS: 37 ( 13 / 24) | Chemotherapy plus HER2 + Targeted therapy | OS, PFS | tissue | WES | 100 mutations | NA |